1 However, despite significant risk reduction, patients with hypertension treated back to optimal blood pressure levels (0 Agatston units (AU) would have higher risk (residual risk) than those who entered the cohort with CAC=0 AU and untreated low LDL‐C levels (<100 mg/dL). Preventive pharmacotherapy instituted after the development of an adverse risk factor, such as use of blood pressure–lowering drugs to treat hypertension, lowers the risk for incident cardiovascular events. Initiation of low‐density lipoprotein cholesterol–lowering therapies earlier in the life course may be the optimal atherosclerotic cardiovascular disease prevention approach in some patients. However, a low‐risk state may not necessarily be restored by statin therapy in primary prevention patients with a coronary calcium score of >0 Agatston units. The results suggest that the low‐risk state can be restored in patients who do not have advanced coronary atherosclerosis as indicated by a coronary calcium score of 0 Agatston units. We used Cox regression to compare the risks for coronary heart disease and CVD between the untreated group with low‐density lipoprotein cholesterol (LDL‐C) 0 Agatston units), and statin status (untreated or treated) with the untreated LDL‐C 0 Agatston units, treated to LDL‐C <100 mg/dL had HRs of 2.6 (95% CI, 1.7–4.2) for coronary heart disease and 1.8 (95% CI, 1.2–2.6) for CVD. Stroke: Vascular and Interventional NeurologyĪt baseline, we grouped 5687 MESA (Multi‐Ethnic Study of Atherosclerosis) participants aged ≥50 years without clinical cardiovascular disease (CVD) by Adult Treatment Panel III statin treatment recommendation and statin treatment status.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
